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Cirrhosis and Advanced Fibrosis in Hispanics
in Texas: The Dominant Contribution of
Central Obesity
Jingjing Jiao1, Gordon P. Watt2, MinJae Lee3,4, Mohammad H. Rahbar3,4,5, Kristina
P. Vatcheva2, Jen-Jung Pan6, Joseph B. McCormick2, Susan P. Fisher-Hoch2, Michael
B. Fallon6‡*, Laura Beretta1‡*
1 Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center,
Houston, Texas, United States of America, 2 School of Public Health, University of Texas Health Science
Center at Houston, Brownsville Regional Campus, Brownsville, Texas, United States of America,
3 Department of Internal Medicine, Division of Clinical and Translational Sciences, The University of Texas
Medical School at Houston, Houston, Texas, United States of America, 4 Biostatistics/Epidemiology/
Research Design (BERD) Core, Center for Clinical and Translational Sciences, The University of Texas
Health Science Center at Houston, Houston, Texas, United States of America, 5 The University of Texas
School of Public Health at Houston, Houston, Texas, United States of America, 6 Department of Internal
Medicine, Division of Gastroenterology, Hepatology and Nutrition, The University of Texas Medical School at
Houston, Houston, Texas, United States of America
‡ These two authors are joint senior authors.
* LBeretta@mdanderson.org (LB); Michael.B.Fallon@uth.tmc.edu (MBF)
Abstract
Liver cirrhosis is a leading cause of death in Hispanics and Hispanics who live in South
Texas have the highest incidence of liver cancer in the United States. We aimed at deter-
mining the prevalence and associated risk factors of cirrhosis in this population. Clinical and
demographic variables were extracted for 2466 participants in the community-based Cam-
eron County Hispanic Cohort in South Texas. Aspartate transaminase to Platelet Ratio
Index (APRI) was used to predict cirrhosis in Cameron County Hispanic Cohort. The preva-
lence of cirrhosis using APRI2 was 0.94%, which is nearly 4-fold higher than the national
prevalence. Using APRI1, the overall prevalence of cirrhosis/advanced fibrosis was
3.54%. In both analyses, highest prevalence was observed in males, specifically in the 25–
34 age group. Risk factors independently associated with APRI2 and APRI1 included
hepatitis C, diabetes and central obesity with a remarkable population attributable fraction
of 52.5% and 65.3% from central obesity, respectively. Excess alcohol consumption was
also independently associated with APRI2. The presence of patatin-like phospholipase
domain-containing-3 gene variants was independently associated with APRI1 in partici-
pants >50 years old. Males with both central obesity and excess alcohol consumption pre-
sented with cirrhosis/advanced fibrosis at a young age. Alarmingly high prevalence of
cirrhosis and advanced fibrosis was identified in Hispanics in South Texas, affecting young
males in particular. Central obesity was identified as the major risk factor. Public health
efforts are urgently needed to increase awareness and diagnosis of advanced liver fibrosis
in Hispanics.
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Liver fibrosis is a wound-healing response characterized by the accumulation of extracellular
matrix (ECM) following liver injury such as hepatitis C, hepatitis B, excess alcohol consump-
tion and nonalcoholic fatty liver disease (NAFLD) [1]. When the injury is sustained, chronic
inflammation and accumulation of ECM persist, leading to a progressive substitution of liver
parenchyma by scar tissue. This process may result in cirrhosis, the end stage of progressive
fibrosis, which is associated with poor outcome and high mortality [2]. Liver cirrhosis is a sig-
nificant health burden, accounting for 49,538 deaths in the United States (US) in 2010 [3].
Liver cirrhosis is the most common risk factor for hepatocellular carcinoma (HCC), a cancer
with few curative treatment options and poor overall survival [4].
The prevalence of cirrhosis worldwide is largely unknown [5].A recent study estimated the
prevalence of cirrhosis in the US to be 0.27% [6]. In a European study among individuals45
years old, the prevalence of advanced fibrosis or cirrhosis was estimated at 0.6% [7]. Ethnic differ-
ences in the incidence of cirrhosis and progression rates have been observed [8]. In the US,
chronic liver disease and cirrhosis is the 6th leading cause of death in Hispanics while it is not
among the 10 leading causes of death for non-Hispanic whites (NHW) and African Americans
[9]. A more aggressive pattern of disease and worse treatment outcome for chronic liver diseases
have also been reported in Hispanics [10]. NAFLD is also more common in Hispanics than in
NHW or African Americans and is the most prevalent chronic liver disease in Hispanics [11–
13].Lifestyle, environmental and genetic risk factors are likely responsible for the ethnic variation
in NAFLD prevalence. One such genetic factor is the patatin-like phospholipase domain-contain-
ing-3 (PNPLA3) gene. PNPLA3 single-nucleotide polymorphisms (SNPs) rs738409 and
rs2281135 are strongly associated with hepatic fat content [14–17] and elevated liver aminotrans-
ferase levels [18, 19]. An association between PNPLA3 rs738409 and cirrhosis or advanced fibro-
sis was also reported in patients with NAFLD [20], alcoholic liver disease [21, 22] or chronic
hepatitis C [23, 24]. The association with cirrhosis has been confirmed using meta-analysis [25].
In this study, we aimed to determine the prevalence and associated clinical features of cirrhosis
and advanced fibrosis in Hispanics in South Texas. To that end, we interrogated a community-
based Hispanic cohort in the US-Mexico Border region, the Cameron County Hispanic Cohort
(CCHC). The CCHC is a ‘Framingham-like’ cohort of a Mexican-American community,
recruited from households, that was initiated in 2004 [26]. The prevalence of obesity (51%), dia-
betes (28%) and elevated liver enzymes (39%) is particularly high in this community [26–28].
Materials and Methods
Data Sources and Subject Parameters
The Cameron County Hispanic Cohort (CCHC) is the data source for this analysis [26]. Our
analysis was performed on CCHC data collected from Jan 29, 2004 to April 18, 2015 and
included 2466 participants from the cities of Brownsville and Harlingen, Texas. The study was
approved by the Committee for the Protection of Human Subjects of the University of Texas
Health Science Center at Houston as HSC-SPH-03-007-B. Written informed consent was given
by participants for their clinical records to be used in this study. Aspartate transaminase (AST) to
Platelet Ratio Index (APRI) score was calculated as follows: (AST/upper-limit of normal)/platelet
count X 100. Upper-limit of normal AST used for calculation was 33IU/L [29]. When partici-
pants have APRI scores frommultiple visits, data from the last visit were used for the analysis.
Diabetes was defined as fasting blood glucose126mg/dl or history of use of diabetic medication.
Obesity was defined as a body mass index (BMI)30kg/m2. Central obesity was defined as waist
circumference 102cm for men and 88cm for women. We defined excess alcohol
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consumption as>2 drinks/d for men and>1 drink/d for women within 1 year before the com-
pletion of data collection [30]. A total of 961 participants were tested for hepatitis C and were
defined as positive if they had a positive test for antibody to hepatitis C as measured using the
ORTHO1HCVVersion 3.0 Test system (Ortho-Clinical Diagnostics, Raritan, NJ). All other
laboratory tests reported were measured at a CLIA approved community reference laboratory
except for insulin, which was measured in the laboratory using Elisa assays (Mercodia1, Upp-
sala, Sweden). PNPLA3 rs2281135 and rs738409 SNPs were genotyped in 1090 participants by
TaqMan 5'-nuclease assays using two predesigned TaqMan probes (Applied Biosystems, Foster
City, CA, C_7241_10 for rs738409 and C_15875080_10 for rs2281135). Genotyping was per-
formed on a ViiA7 Real time PCR system (Applied Biosystems, Foster City, CA).
Statistical Analysis
The analysis took into account the study design and used age- and gender-adjusted sampling
weights to scale the sample to the underlying population. In the analysis, we also accounted for
clustering effect among participants from the same household. Categorical variables for demo-
graphic and clinical characteristics were summarized in weighted percentages, and continuous
variables were summarized using weighted means, standard errors and medians. The Rao-
Scott design-adjusted chi-square test was used to test for equality of proportions of categorical
variables between the cirrhotic and non-cirrhotic participants. Univariable survey-weighted
logistic regression analyses were performed to assess the effects of continuous variables on cir-
rhosis status. Multivariable weighted data analyses were conducted using mixed effect logistic
regression models that account for correlations among survey-weighted observations within/
between multiple cluster levels. Multicollinearity and interaction effects between the indepen-
dent variables and potential confounders were examined while developing multivariable mod-
els. ANOVA was used to test association between APRI score and 2 PNPLA3 SNPs (rs2281135
and rs738409). Multiple pairwise comparisons were evaluated by Tukey's test. PNPLA3 SNPs
rs2281135 and rs738409 were highly correlated (r = 0.91) and separate survey-weighted logistic
regression models were created using rs738409. Each SNP was considered as categorical vari-
ables with 3 categories (WT allele, 1 risk allele and 2 risk alleles). Population Attributable frac-
tion (PAF) is an estimate of the burden of the disease in the population that could be avoided if
the exposure to a specific risk factor was reduced or eliminated. Based on the final multivari-
able weighted logistic regression models adjusted attributable fractions were derived for each of
the factors of interest included in the models. The category-specific attributable risk fraction
was estimated by PAFi ¼ piðORi1ÞORi x100% where ORi is the i-th category specific weighted
adjusted odds ratio for cirrhosis calculated based on the logistic regression model and pi is
the weighted proportion of all cases of cirrhosis falling into i-th exposure level of a categorical
variable with k levels and reference level denoted by i = 1. The category-specific attributable
risk factor for the unexposed group (i = 1) is 0 since ORi is 1 by definition. The total
population attributable risk fraction for a categorical variable with k levels was estimated
by PAF ¼ Pki¼2 PAFi. A two-sided test with P<0.05 was considered significant for all analyses.
All statistical analyses were conducted using SAS 9.4 (SAS Institute, Inc., Cary, North
Carolina).
Results
Prevalence of Cirrhosis in Hispanics in Cameron County
The prevalence of cirrhosis in Hispanics in Cameron County was determined using the Aspar-
tate transaminase (AST) to Platelet Ratio Index (APRI) score2. Using this approach, the
Cirrhosis and Advanced Fibrosis in Hispanics in Texas
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overall prevalence of cirrhosis in Cameron County was estimated as 0.94% (Fig 1A). High prev-
alence (1.28%) was observed in the 45–54 age group in our study group. However, the highest
prevalence (1.92%) was observed in the 25–34 age group. This high prevalence in the young
age group was mostly contributed by males (Fig 1A).
Demographic, Clinical and Laboratory Variables by Cirrhosis Status
The demographic, clinical and laboratory features of the participants with cirrhosis (Table 1)
included higher levels of liver enzymes, insulin and glucose and significantly lower levels of
high density lipoprotein (HDL). Cirrhosis also affected Hispanic females in South Texas. Cir-
rhosis was also present in a younger age group in Hispanics in the CCHC (mean = 45 years).
Among the known risk factors associated with cirrhosis, 11.4% of the participants with cirrho-
sis reported excess alcohol consumption and 14.2% had hepatitis C.
Prevalence of Cirrhosis or Advanced Fibrosis in Hispanics in Cameron
County
Two large meta-analyses have reported that using APRI2, the sensitivity and specificity to
detect cirrhosis are 31–46% and 89–91%, whereas when using APRI1, the sensitivity
increases to 66–76% with a slight decrease in specificity [31, 32]. Using APRI1 will also iden-
tify some subjects with advanced fibrosis. We therefore expanded our analysis to cirrhosis/
advanced fibrosis in Hispanics in Cameron County by using APRI1. The overall prevalence
of cirrhosis/advanced fibrosis was 3.54% (Fig 1B). While the highest prevalence was observed
in participants older than 65 years old (4.91%), high prevalence was also observed in the 25–34
age group (4.65%). With the exception of the 45–54 age group in which the prevalence was
3.05% in females, the prevalence was significantly higher in males than in females in all age
groups. The overall prevalence was 5.9% in males and 1.72% in females. The demographic,
clinical and laboratory features of the participants with cirrhosis/advanced fibrosis are pre-
sented in Table 2. Participants with cirrhosis/advanced fibrosis were more likely to be male, to
have diabetes, to present with higher BMI, waist circumference, fasting triglyceride, glucose
and insulin levels. Participants with cirrhosis/advanced fibrosis were also most likely to have
hepatitis C (7.3%). Females with cirrhosis/advanced fibrosis had higher HCV prevalence
Fig 1. Prevalence of cirrhosis (A) and of advanced fibrosis (B) by age group.
doi:10.1371/journal.pone.0150978.g001
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(11.5%) and presented with significantly higher bilirubin levels (Table 2). In contrast, hyperlip-
idemia was observed only in males (Table 2).
Factors Associated with Cirrhosis and Advanced Fibrosis based on
Multivariable Logistic Regression Analysis
To determine the factors independently associated with cirrhosis (APRI2) or cirrhosis/
advanced fibrosis (APRI1), multivariable logistic regression analysis was performed. Hepati-
tis C (adjusted Odds Ratio (OR) = 23.47 (95% CI = 3.14–175.41) p = 0.002), diabetes (adjusted
OR = 6.19 (95% CI = 0.96–39.85) p = 0.06), excess alcohol consumption (adjusted OR = 3.98
(95% CI = 0.95–16.64) p = 0.06) and central obesity (adjusted OR = 4.18 (95% CI = 0.43–
Table 1. Demographic, clinical, and laboratory variables by cirrhosis status (APRI 2 cutoff).
Variables APRI2 (N = 23) APRI<2 (N = 2443) P




Diabetes 42.2% 21.6% 0.09
Excess alcohol consumption 11.4% 4.5% 0.13
Blood tests
AST 150.7(21.7)-123.2 29.1(0.6)-24.6 < .001
ALT 119.1(29.7)-71.3 36.3(0.8)-30.7 < .001
ALP 111.9(25.6)-81.6 67.2(2.0)-75.1 < .001
Platelets 133.2(21.8)-140.8 244.1(2.1)-237.2 < .001
total bilirubin 1.1(0.4)-0.5 0.5(0.1)-0.4 0.10
Creatinine 0.9(0.1)-0.7 0.8(0.01)-0.7 0.19
HCV antibody 14.2% 2.2% < .001
HBV surface antigen 5.3% 1.6% 0.22
fasting glucose 144.4(28.2)-101.1 110.2(1.6)-96.4 0.04
fasting insulin 19.8(2.9)-14.5 14.7(0.3)-11.6 0.008
fasting triglycerides 196.9(46.2)-120.7 152.4(4.2)-123.9 0.11
HDL 37.7(2.9)-37.5 46.3(0.5)-44.6 0.01
LDL 94.5(13.2)-108.2 104.7(1.2)-101.8 0.48
insulin resistance (HOMA) 9.0(2.1)-5.3 4.1(0.1)-3.0 0.08
BMI 30.0(1.2)-29.3 31.1(0.3)-30.3 0.38
waist circumference 109.9(5.8)-103.1 104.2(0.7)-102.9 0.28
systolic blood pressure 121.5(3.9)-123.9 119.0(0.7)-115.9 0.49
diastolic blood pressure 76.0(2.0)-74.4 73.7(0.4)-73.2 0.25
metabolic syndrome components
waist circumference (cm) (>102/men—>88/women) 69.0% 73.0% 0.75
fasting plasma glucose (>110mg/dL) 42.6% 23.9% 0.14
blood pressure (>130/85mm Hg) 32.1% 23.1% 0.49
Triglycerides (>150mg/dL) 43.0% 36.0% 0.63
low HDL (mg/dL) (<40/men—<50/women) 60.5% 49.9% 0.45
Data are presented as mean (SE)-median or as frequency (%).
AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; HCV, hepatitis C virus; HBV, hepatitis B virus; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; HOMA, Homeostasis Model Assessment; BMI, body mass index.
doi:10.1371/journal.pone.0150978.t001
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Table 2. Demographic, Clinical and Laboratory Variables by Cirrhosis/Advanced Fibrosis Status (APRI 1 cutoff).



























Diabetes 42.6% 21.0% 0.004 41.1% 21.1% 0.04 46.4% 21.0% 0.003

























































total bilirubin 0.7(0.1)-0.5 0.5(0.1)-0.4 0.42 0.6(0.04)-
0.5
0.7(0.2)-0.4 0.34 1.0(0.4)-0.4 0.4(0.01)-0.3 0.003







HCV antibody 7.3% 1.8% 0.004 5.8% 2.9% 0.33 11.5% 0.9% <
.001




























































insulin resistance (HOMA) 8.0(1.0)-5.8 3.9(0.1)-2.9 <
.001


























































45.1% 23.3% 0.006 44.9% 26.7% 0.09 45.6% 20.7% 0.004
(Continued)
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40.59) p = 0.22) were associated with cirrhosis (Table 3). In the context of cirrhosis/advanced
fibrosis, independent risk factors were hepatitis C (adjusted OR = 53.70 (95% CI = 4.97–
580.48) p = 0.001), diabetes (adjusted OR = 5.09 (95% CI = 1.77–14.67) p = 0.003), central obe-
sity (adjusted OR = 5.40 (95% CI = 1.11–26.33) p = 0.04) and male gender (adjusted OR = 8.03
(95% CI = 2.48–26.01) p< .001) (Table 3). Excess alcohol consumption was not found as a sta-
tistically significant risk factor for cirrhosis/advanced fibrosis in this population. BMI was also
not found as an independent risk factor for cirrhosis nor advanced fibrosis. Approximately
35.4% of cirrhosis and 34.4% of cirrhosis/advanced fibrosis could be attributed to diabetes
(Table 3). Remarkably, 52.5% of cirrhosis and 65.3% of cirrhosis/advanced fibrosis could be
attributed to central obesity (Table 3).
Patatin-like phospholipase domain-containing-3 (PNPLA3) SNPs
Since PNPLA3 SNP rs738409 has been reported to be associated with liver fibrosis and
PNPLA3 SNPs rs738409 and rs2281135 have been associated with elevated transaminases in
CCHC participants, correlation analysis between these two SNPs and APRI scores was
Table 2. (Continued)
















34.8% 22.7% 0.17 37.1% 28.1% 0.45 28.6% 18.8% 0.33
Triglycerides (>150mg/dL) 55.3% 35.4% 0.01 65.1% 38.3% 0.005 28.6% 33.2% 0.59
low HDL (mg/dL)(<40/men–
<50/women)
56.3% 49.7% 0.46 50.1% 40.1% 0.39 72.8% 56.9% 0.09
Data are presented as mean (SE)-median or as frequency %.Data are presented for all participants and stratified by gender.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; HCV, hepatitis C virus; HBV, hepatitis B virus; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; HOMA, Homeostasis Model Assessment; BMI, body mass index.
doi:10.1371/journal.pone.0150978.t002
Table 3. Factors Associated with cirrhosis (APRI2) and cirrhosis/advanced fibrosis (APRI1) based onmultivariable logistic regression models.
A Cirrhosis model
Variables Adjusted a Odds Ratio 95% CI P PAF
Hepatitis C 23.47 3.14–175.41 0.002 13.6%
Diabetes 6.19 0.96–39.85 0.06 35.4%
Excess alcohol consumption 3.98 0.95–16.64 0.06 8.5%
Central obesity 4.18 0.43–40.59 0.22 52.5%
Male 4.30 0.45–40.72 0.20
B Cirrhosis/advanced fibrosis model
Variables Adjusted a Odds Ratio 95% CI P PAF
Hepatitis C 53.70 4.97–580.48 0.001 7.2%
Diabetes 5.09 1.77–14.67 0.003 34.4%
Excess alcohol consumption 1.31 0.21–8.09 0.77 2.0%
Central obesity 5.40 1.11–26.33 0.04 65.3%
Male 8.03 2.48–26.01 < .001
PAF, population attributable fraction; CI, confidence interval. Analysis is based on n = 725 participants.
a Lipidemia and total bilirubin were also adjusted in this multivariable model (not listed)
doi:10.1371/journal.pone.0150978.t003
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performed. Overall, 47.5% of the participants with predicted cirrhosis carried 2 risk alleles of
PNPLA3 SNP rs2281135 compared to 21.2% of the non-cirrhotic participants (p = 0.03). Simi-
larly, 49.1% of the participants with predicted cirrhosis carried 2 risk alleles of PNPLA3 SNP
rs738409 compared to 25.7% in non-cirrhotic group, although the difference did not reach sig-
nificance (Fig 2A). There were significantly more participants in the cirrhosis/advanced fibrosis
group who carried 2 risk alleles of both SNPs compared to participants with no predicted
advanced fibrosis (35.0% vs 20.0% for SNP rs2281135; p = 0.01 and 39.6% vs 24.4% for SNP
rs738409; p = 0.02) (Fig 2A). Participants with 2 PNPLA3 rs2281135 risk alleles had signifi-
cantly higher APRI scores (0.74±0.07) compared to participants carrying no (0.45±0.02) or 1
(0.55±0.04) risk allele (p< .001 and p = 0.01, respectively) (Fig 2B). Similarly, participants
Fig 2. PNPLA3 SNPs and APRI scores. (A) PNPLA3 SNPs genotype distribution according to cirrhosis (APRI cutoff of 2) and cirrhosis/advanced fibrosis
(APRI cutoff of 1) status. APRI scores in CCHC participants carrying PNPLA3 rs2281135 (B) and rs738409 (C) SNPs. (D) Association between PNPLA3
rs738409 and cirrhosis/advanced fibrosis (APRI cutoff of 1) based on multivariable logistic regression model. APRI = Aspartate transaminase to Platelet
Ratio Index; SNP = single-nucleotide polymorphisms; PNPLA3 = patatin-like phospholipase domain-containing-3; CCHC = Cameron County Hispanic
Cohort.
doi:10.1371/journal.pone.0150978.g002
Cirrhosis and Advanced Fibrosis in Hispanics in Texas
PLOS ONE | DOI:10.1371/journal.pone.0150978 March 7, 2016 8 / 14
with 2 PNPLA3 rs738409 risk alleles had significantly higher APRI scores (0.72±0.06) com-
pared to participants carrying no (0.44±0.02) or 1 (0.54±0.04) risk allele (p< .001 and
p = 0.01, respectively (Fig 2C). Age was found to be a significant effect modifier of the relation-
ship between rs738409 and cirrhosis/advanced fibrosis status (p< .001). Odds of cirrhosis/
advanced fibrosis status for 2 risk alleles were significantly higher than those for 1 risk allele in
participants >50 years old (adjusted OR = 7.83) based on the multivariable logistic regression
model (Fig 2D).
Risk Factor Synergy in Participants with Cirrhosis/Advanced Fibrosis
Finally, we characterized the presence of the identified risk factors (diabetes, central obesity,
hepatitis C, excess alcohol consumption, and 2 PNPLA3 risk alleles) in each of the individuals
that had APRI1. While at least one of these risk factors was present in all females, none were
identified in 13% of males. These males were young with a median age of 32 years. The most
common single risk factor observed in individuals with cirrhosis/advanced fibrosis was central
obesity accounting for 13% of males and 11.6% in females. These individuals with central obe-
sity as the single observed risk factor were older with a median age of 54.5 years (Table 4). The
combination of central obesity and diabetes was observed in 21.4% of males and in 30.2% of
females. Interestingly, the combination of central obesity and excess alcohol consumption in
males led to the development of cirrhosis/advanced fibrosis at a significantly younger age
(median 30 years) compared to central obesity alone (p = 0.02) or central obesity and diabetes
combined (p = 0.01) (Table 4). In females, an additive effect between central obesity and 2
PNPLA3 risk alleles was observed with 51.2% showing both risks regardless of the presence of
diabetes (Table 4).
Discussion
This is the first study to estimate the prevalence of cirrhosis in Hispanic adults in the US, focus-
ing here on Hispanics in South Texas. To that end, we investigated a community-based
Table 4. Percentage andmedian age of participants with cirrhosis/advanced fibrosis, with central
obesity (CO) alone or in combination with diabetes (DM), excess alcohol consumption (Alc) or 2 risk
alleles of PNPLA3 rs738409 (SNP) in males and in females.
A Males
Risk Factors % Median Age P
CO 13.0 43 0.02b
CO+DM 21.4 54 0.009c
CO+Alca 12.5 30
B Females





CO, central obesity; DM, diabetes mellitus; SNP, single nucleotide polymorphism.
a excess alcohol consumption
bp value between CO and CO+Alc
cp value between CO+DM and CO+Alc
d 2 risk alleles of PNPLA3 rs738409
doi:10.1371/journal.pone.0150978.t004
Cirrhosis and Advanced Fibrosis in Hispanics in Texas
PLOS ONE | DOI:10.1371/journal.pone.0150978 March 7, 2016 9 / 14
Hispanic cohort in Cameron County. First, we applied a strategy recently employed to estimate
the prevalence of cirrhosis in the general US population, using a non-invasive scoring system
(APRI2) [6]. In addition to this direct comparison to national data, we also used a APRI1
to enhance sensitivity for detecting cirrhosis, supported by the findings of two large meta-anal-
yses [31, 32].
Overall, we observed a 4-fold higher prevalence of cirrhosis in Hispanics in South Texas
compared to the general US population. Several features of liver cirrhosis specific to this popu-
lation compared to the overall US population were identified. The national prevalence steadily
increased with age and peaked at 0.57% in those between 45 and 54 years old [6].Similarly,
higher prevalence (1.28%) was observed in the 45–54 age group in our study group. However,
in contrast to the national study, the highest prevalence (1.92%) was observed in the 25–34 age
group. This high prevalence in the young age group was mostly contributed by males. In addi-
tion, while 72.7% of participants with predicted cirrhosis in the US were males, Hispanic
females in South Texas were significantly affected Similarly, while viral hepatitis accounts for
46.7% of cirrhosis in the US population [6], it accounts for only 13.6% of cirrhosis among His-
panics in South Texas. Finally, a strikingly high prevalence of cirrhosis was observed in young
Hispanics males (3.64% in 25–34 age group) while older age is an independent risk factor for
cirrhosis in the national study. The early onset of cirrhosis in Hispanics is consistent with a pre-
vious epidemiological report [8]. Development of cirrhosis in patients under age 35 has been
suggested to be related to adolescent onset of alcohol and parenteral heroin abuse [33]. The sta-
tus of intravenous drug use and alcohol intake in adolescents in this cohort are currently
unknown. Hispanics are the ethnic group with the highest prevalence of NAFLD in children
and adolescents [34] and cases of children with NAFLD who develop cirrhosis in young adult-
hood have been reported [35]. While the prevalence of pediatric NAFLD in this population is
currently unknown, a study performed on 325 high school students in Cameron County
showed that 40% of these adolescents had high waist circumference and 27% exhibited insulin
resistance [36].
A main finding of our study is the major contribution of central obesity to cirrhosis/
advanced fibrosis in Hispanics in South Texas. While an association between central obesity
and fibrosis progression in the setting of NAFLD has been previously suggested [37, 38], this is
the first report identifying central obesity as the most frequent risk factor associated with cir-
rhosis/advanced fibrosis in a population. Remarkably, males with both central obesity and
excess alcohol consumption presented with cirrhosis/advanced fibrosis at a significantly youn-
ger age (median age: 30) than males with central obesity alone or with central obesity and dia-
betes, suggesting for the first time a synergistic effect between central obesity and excess
alcohol consumption. For 13% of males with predicted advanced fibrosis, no known risk factor
was identified. These participants were also young (median age: 32). We can speculate that
alcohol consumption was underestimated in this group and that these participants may have a
history of central obesity in adolescence or earlier.
Genetic factors are involved in the development of liver cirrhosis [39] and we found a corre-
lation between increased APRI scores and 2 risk alleles of PNPLA3 SNPs in the CCHC. Based
on multivariable analysis, the carrier of 2 risk alleles of these SNPs was identified as an inde-
pendent risk factor associated with cirrhosis/advanced fibrosis. Our findings are consistent
with a study by Krawczyk et al. in a cohort of 899 European patients with chronic liver diseases,
where homo-and heterozygous carriers of the G allele of rs738409 were at increased risk for
developing cirrhosis and advanced fibrosis [40]. Besides PNPLA3, other genetic factors are
involved in cirrhosis or fibrosis progression. In NAFLD patients, carriers of the minor allele of
non-synonymous SNP rs58542926 in transmembrane 6 superfamily member 2 (TM6SF2)
were found to have an increased prevalence of advanced fibrosis [41]. Moreover, a cirrhosis
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risk score consisting of SNPs in 7 genes (AP3S2, AQP2, AZIN1, DEGS1, STXBP5L, TLR4, and
TRPM5) has been shown to predict fibrosis progression in HCV infected patients [42, 43].
Whether additional genetic factors influence the risk of fibrosis in the CCHC remains an area
for future study.
This study has several limitations. The identification of cohort subjects with advanced fibro-
sis or cirrhosis is based on using a non-invasive marker APRI that has not been validated in
population cohorts. APRI has been primarily validated among patients with chronic liver dis-
ease and there can be reasons for false-positive APRI elevations in a population-based sample
including drug induced liver injury, acute alcoholic hepatitis or non-cirrhosis related thrombo-
cytopenia. In addition, HCV and HBV were tested in 50% of the cohort participants. The miss-
ing data could therefore affect the PAF analysis when estimating the contribution of these
factors to liver cirrhosis or cirrhosis/advanced fibrosis.
Liver cancer is the fastest growing cause of cancer-related mortality in the United States.
Liver cirrhosis is the most common risk factor for hepatocellular carcinoma (HCC) and there-
fore the risk factors for HCC and cirrhosis largely overlap. These include genetic factors such
as PNPLA3. PNPLA3 rs738409 2 risk alleles has been identified a risk factor for developing
HCC associated with NAFLD [44], alcoholic liver disease [45] or chronic HCV infection [46,
47].The role of central obesity as a risk for HCC is also emerging as shown in a large European
study [48]. The high prevalence of cirrhosis in Hispanics in South Texas seems to correlate
with the high prevalence of HCC in this population. Recent reports showed that the incidence
of HCC is the highest among Hispanics in South Texas [49, 50]. In Cameron County, liver can-
cer ranked third among cancers in males and sixth in females based on self-reported data [51].
Because the survival rate of HCC is dismal, it is critical to identify those at high risk and enroll
them in surveillance and prevention programs. Our study can therefore contribute to that
effort. Affordable non-invasive diagnostic means to detect and stage liver fibrosis are urgently
needed for this underserved population.
Conclusions
We found an overall prevalence of 0.94% for cirrhosis and of 3.54% for cirrhosis/advanced
fibrosis in the CCHC. This high prevalence of cirrhosis and advanced fibrosis in South Texas
affects in particular young Hispanic men. The majority of cirrhosis and advanced fibrosis risk
was contributed by central obesity and diabetes. Synergistic effects were also observed between
central obesity and excess alcohol consumption. These findings are an important first step in
developing interventions to reduce liver disease burden in this underserved population. Public
health efforts are needed to understand the unique pattern of cirrhosis and advanced fibrosis in
Hispanics in South Texas, to reduce this disease burden and to identify those to whom HCC
surveillance may be targeted.
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